Understanding the AMP Results and So Much More

July 8, 2021

We’re delighted to share our new publication Understanding Results of the AMP Trials. The first results of these landmark trials were announced in early 2021, but their implications will be echoing for years to come. This guide provides a foundation for advocates.

The AMP trials evaluated the ability of a broadly neutralizing antibody (bNAb), called VRC01, to protect against HIV. The trials showed that VRC01 did not reduce the overall risk of acquiring HIV. However, VRC01 protected some individuals from infection by HIV viruses that were particularly vulnerable or “sensitive” to the antibody. Together these results mean AMP will inform future bNAb and vaccine studies. Read Understanding Results to learn more; listen to our Px Pulse podcast to dive into the AMP trials; and check out AVACer Daisy Ouya’s commentary on the AMP trials in the latest issue of IAVI’s Voices: Community Perspectives on Clinical Research.

Also, in case you missed it, we’re highlighting a few other important resources to inform prevention advocacy: